Home RF & Microcurrent Device Patents: Who Leads 2026
- 85.1% concentration. The top 5 of 12 ranked assignees account for 97 of the 114 records in scope — filing here is dominated by a small group, not a fragmented field.
- Filing peaked in 2019. 37 records that year is the high point so far; 2021-to-2024 filing fell 23%, from 13 to 10 records, though 2025-2026 figures are still incomplete.
- Electrotherapy claims dominate. A61N covers 96.5% of the 114 records, while adjacent classes like healthcare informatics and physical therapy sit in the low teens — signalling where claim space is thinner.
Filing growth compares 2021 (13 records) with 2024 (10) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 114 records in scope (CR5), not by the ranked leaders only.
What the patent record shows
Home radiofrequency and microcurrent devices sit at the intersection of consumer electronics and low-power electrotherapy. The search scope here combines device categories — home radiofrequency device, microcurrent device, facial toning device — with the practical engineering constraints that make them safe for unsupervised home use: power limit, electrode contact, conductive gel, skin temperature, safety interlock, usage frequency. That pairing is deliberate: a device claim without a safety or contact-sensing limitation rarely survives home-use regulatory scrutiny, so the corpus is weighted toward records that address both.
114 published records fall within this scope between 2015 and the 2026-07-31 cut-off. The assignee ranking returns 12 companies, and filing activity is heavily concentrated among the first few names on that list rather than spread evenly across the field.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 114-record dataset: annual filing volume, and the IPC subclasses those filings claim against.
Filing trend, 2017-2026
Filings rose from 15 in 2017 to a peak of 37 in 2019, then eased back. The 2021-to-2024 window shows a 23% decline, from 13 to 10 records. 2025 and 2026 figures are undercounted because publication typically lags filing by around 18 months, so the most recent two years should not be read as a continued drop.
IPC subclass composition
A61N (electrotherapy and radiation therapy) appears in 96.5% of the 114 records, confirming that nearly every filing in scope claims some form of electrotherapeutic delivery. G06F and G16H each appear in 14.0% of records, reflecting a smaller but consistent layer of digital-control and informatics claims. H05K (11.4%), A61H (9.6%), A61B and A61F (5.3% each), and A61K (2.6%) round out the composition — each a narrower slice of hardware, physical-therapy, diagnostic, or formulation claims layered on top of the core electrotherapy function.
Shares are the percentage of the 114 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Home Radiofrequency and Microcurrent Devices with Eureka
This page is one run against one query. Ask Eureka your own question about home radiofrequency and microcurrent devices and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a representative filing
US11318307B2 — Fingertip mounted microcurrent device for skin
A device for delivery of TENS current or electrostimulation has a first skin-contact electrode mounted on a non-conductive fingertip base, with a connection to a TENS current source, and a second skin-contact electrode mounted on the same or a second non-conductive fingertip base. A control and power unit supplies TENS current between the two electrodes when both are positioned against the skin.Filed by NSE Products, Inc.; granted 2022-05-03.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6606519B2 | Microcurrent therapy device components stack and conductive pad | 58 |
| 2 | US6408211B1 | Microcurrent therapy device | 48 |
| 3 | US20220062634A1 | Microcurrent-stimulation-therapy apparatus and method | 33 |
| 4 | US20210162212A1 | Fingertip mounted microcurrent device for skin | 22 |
| 5 | US20170266445A1 | Microcurrent device for the treatment of visual disease | 19 |
| 6 | US20210308452A1 | Modulated waveform treatment device and method | 18 |
| 7 | US20230124830A1 | Current control system for skin treatment device | 17 |
| 8 | US20170266446A1 | Microcurrent device and method for the treatment of visual disease | 12 |
| 9 | WO2020132337A1 | Microcurrent-stimulation-therapy apparatus and method | 11 |
| 10 | US11007367B2 | Microcurrent device for the treatment of visual disease | 11 |
Citation counts reflect influence within the searched corpus and favour older filings; they are not a measure of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three findings that shape where a new filing is likely to clear prior art, and where it will land in a crowded queue.
A small group holds most of the claim space
With 97 of 114 records held by five assignees, and the leader alone accounting for 38, this is not a fragmented field where a new entrant can expect open ground by default. Freedom-to-operate review against the leading names is a prerequisite, not a formality.
Activity has cooled since its 2019 peak
The 2021-to-2024 window shows filings falling 23%, from 13 to 10 records. That is a real signal over a complete window, but 2025-2026 data is still filling in given the typical 18-month publication lag, so it should not be read as the field going quiet.
Electrotherapy claims are near-universal; adjacent classes are thin
Almost every record claims some electrotherapy element, but only 14.0% touch healthcare informatics (G16H) or digital processing (G06F), and just 9.6% touch physical therapy/massage (A61H). That gap between the core claim and its adjacent-technology layers is where less-crowded claim language tends to sit.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to home radiofrequency and microcurrent devices, with the prior art for and against each one.
Who is filing, and where the field is moving
The ranked assignee list is short — 12 companies — and the leading names have gone quiet in the most recent complete year, which changes how a competitive read of this space should be framed.
One assignee holds a third of all records in scope
The leading name accounts for 38 of 114 records, well ahead of fifth place at 6. That gap between first and fifth is itself a finding: this is a field with one dominant filer rather than several evenly matched competitors.
Beyond the top 10, filing activity is minimal
The top 10 of 12 ranked assignees combine for 98.2% of all records, leaving almost nothing for names outside that group. A new entrant is not competing against a broad field of small filers; it is competing against a handful of established portfolios.
Recent-year filing has paused across leading names
Several of the assignees with the largest historical portfolios show zero filings in the latest tracked year, a -100% year-on-year change. Given the publication lag, this likely reflects incomplete recent data rather than an actual exit from the field, but it is worth monitoring as later filings publish.
| Assignee | Recent year | YoY |
|---|---|---|
| I LUMEN SCI INC | 0 | -100% |
| NSE Products, Inc. | 0 | -100% |
| Nova Oculus Canada Mfg ULC | 0 | — |
| NEWMARK | 0 | — |
| Nova Oculus Partners LLC | 0 | — |
| MACUMIRA MEDICAL DEVICES INC | 0 | — |
| Carol Cole Company | 0 | — |
| NEWCARE PRODS | 0 | — |
Where to take this research
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, portfolio strategy, or identifying open claim space.
Run a freedom-to-operate check against the leading assignee
With one assignee holding 38 of 114 records, any new filing in core electrotherapy delivery should be checked against that portfolio specifically before drafting claims.
Explore assignee portfolios in EurekaTrack the 2025-2026 publication gap
Recent-year filings are still incomplete because of the 18-month publication lag. Re-checking the trend in six to twelve months will show whether the 2021-2024 decline continued or reversed.
Set up trend monitoring in EurekaDraft around the under-claimed adjacent classes
G16H, G06F and A61H each sit well below A61N in record share, suggesting claim language combining electrotherapy delivery with informatics or physical-therapy elements has more open space than core electrode claims.
Search adjacent-class prior art in EurekaCommon questions about this landscape
The assignee ranking in this dataset returns 12 companies, and the field is heavily concentrated: the top 5 of those 12 hold 97 of the 114 records in scope, or 85.1%. The single leading assignee alone accounts for 38 records, well ahead of the fifth-ranked name at 6. This means competitive analysis in this space should focus on a small set of established portfolios rather than a broad field of filers.
Filing peaked in 2019 at 37 records and has since eased; the most recent complete comparison window, 2021 to 2024, shows a 23% decline from 13 to 10 records. However, publication typically lags filing by around 18 months, so the 2025 and 2026 figures in this dataset are undercounted and should not be read as confirmation the field has gone quiet. A fair read is that the field has cooled from its 2019 peak, with the last two years still an open question.
A61N, the electrotherapy and radiation therapy class, appears in 96.5% of the 114 records in scope, making it the near-universal claim category for this technology. Smaller but consistent shares go to healthcare informatics and digital data processing, each around 14.0%, and physical therapy or massage claims at 9.6%. Diagnostic, implant, and medicinal-preparation classes each sit under 6%, indicating those are minor overlaps rather than core claim areas.
US11318307B2, assigned to NSE Products and granted 2022-05-03, claims a fingertip-mounted device with two skin-contact electrodes on non-conductive fingertip bases, connected to a TENS current source, where a control and power unit supplies current between the electrodes once both are positioned against the skin. That claim structure is specific to the fingertip-mounted, dual-electrode TENS delivery mechanism; it does not block electrode designs mounted elsewhere on the body or devices using different current-source architectures. Anyone designing a fingertip-based microcurrent device should review this claim closely, but the broader home-microcurrent category has other viable electrode-placement approaches outside its scope.
The clearest under-claimed branches sit in the classes adjacent to the dominant A61N cluster: healthcare informatics (G16H) and digital data processing (G06F) each appear in only 14.0% of the 114 records, and physical therapy or massage integration (A61H) in 9.6%. Combining core electrotherapy delivery with usage-tracking software, automated safety interlocks, or contact-quality sensing is comparatively underrepresented compared to the electrode and current-delivery claims that dominate the corpus. A first claim in this space would likely pair a physical safety mechanism, such as electrode-contact sensing or temperature cutoff, with a software or data layer rather than claiming the electrotherapy delivery mechanism alone.
Research Home Radiofrequency and Microcurrent Devices in depth with Eureka
Go past this page: query the whole home radiofrequency and microcurrent devices corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.